This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getting the correct food allergy diagnosis leads to increased diet diversity and potentially improved nutrition when suspected allergies are ruled out, making it critical to take the right diagnostic approach from the beginning.
CardioSTAT has now become the leading wearable cardiac monitoring solution in Canada. The CardioSTAT solution differentiates itself by being the most flexible solution available: physicians have a choice of multiple monitoring durations ranging from 24 hours to 14 days. See Full Press Release at the Source: Icentia Receives U.S.
While some medical issues cause obesity, the most significant cause is eating the wrong foods and lack of exercise. A New York Times article said, “Poor diet is the leading cause of mortality in the U.S.” These people hand cards, telling physicians not to weigh them to nurses. It leads to a lack of accountability.
The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Patients trust their doctors, so the accelerated approval process must be modified to increase their trust with physicians and explain to patients precisely what accelerated drug approval means. Do patients care?
30, 2021, the study’s lead author, Thomas J. It isn’t real food; it is the packaged, highly refined, chemically-laden products marketed to us as “food” that is killing us and will continue to do so until we reframe what is being perpetrated on consumers in terms of addiction. . 1, 2020, and Sept.
In terms of pulling, our communities team will go out and try to identify who are the leading KOLs from a space and invite them to jump on a Zoom call to explain how the platform works, why they should be excited about it, why they should buy into the process, and see if they are interested in producing content.
Also, if you’re reading this episode, whether you’re trying to break in, already or a medical sales professional, or you’re leading the way, you’re going to learn something that you probably haven’t heard before. He has experienced quite a few things in his career that are not common for someone in his position.
Diabetes can lead to serious health complications like heart disease and stroke, so it’s important to take steps to avoid developing the disease if possible. There are many risk factors for type 2 diabetes, but one of the biggest is a poor diet high in processed foods and added sugar.
In times of stress too many people turn to bad foods as an outlet. HCP’s and insurance companies too often fail to have a conversation about a patient’s weight and lack of exercise which in turn leads to more health problems and higher healthcare costs.
Gardner Family Center for Parkinson’s Disease Research Endowed Chair in UC’s Department of Neurology and Rehabilitation Medicine and a physician at the UC Gardner Neuroscience Institute explained. and Joan A. He noted that this means the treatment dose needs to be increased or administered more often.
Reimbursement for Community Health Integration, Social Determinants Risk Assessment, and Principal Illness Navigation On November 2, the Centers for Medicare and Medicaid Services (“CMS”) released the 2024 Medicare Physician Fee Schedule (“2024 MPFS”) final rule.
Reimbursement for Community Health Integration, Social Determinants Risk Assessment, and Principal Illness Navigation On November 2, the Centers for Medicare and Medicaid Services (“CMS”) released the 2024 Medicare Physician Fee Schedule (“2024 MPFS”) final rule.
Now working as a woman in pharma, Dr Ekaterina Malievskaia highlighted her female inspirations in the industry, two of which have held leading roles at Bristol Myers Squibb and the US Food and Drug Administration (FDA). I am a physician by training, and I worked in New York hospital emergency rooms for many years.
In February 2022, HeartBeam partnered with LIVMOR to build a HeartBeam-branded version of LIVMOR’s FDA-cleared Halo cloud-based software platform to connect physicians and patients. HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.
Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). Imran joined Oncology US Medical Affairs in 2018 as the Therapeutic Area Lead, Lymphoma and Myeloid Malignances.
Innovation S-curve for the pharmaceutical industry Periodontitis drugs is a notable innovation area in the pharmaceutical industry Periodontal diseases, which may lead to the damage of teeth or bone, are caused by infections and inflammation of the gums and bone that surround and support the teeth.
Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling submission of biologics licence applications (BLAs) to the US Food and Drug Administration (FDA) for exagamglogene autotemcel (exa-cel) to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
the leading provider of convenient, clinical-grade blood collection solutions, announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+ lancet as a Class II medical device. Tasso, Inc., Tasso+ device-based solutions with Class II clearance will be widely available to customers across the country in Q4 2022.
Creating a layman’s lexicon that speaks to patients plainly, directly, and clearly will bridge the “gap of understanding” between HCP and patient, leading to quicker diagnosis and treatment decisions. But now, as patient-to-HCP conversations happen less frequently, especially in-person, words – the right ones – matter more than ever.
Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System. The EndoStim System consists of an implantable neurostimulation device and lead placed via a quick, minimally-invasive laparoscopic procedure. About the EndoStim System. About EndoStim.
CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006.
Tyber Medical LLC, the global, leading private-label medical device provider for major orthopedic trauma, extremity, and spine companies, has been awarded a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new NiTy+ One-Shot Staple Fixation System.
7008), which allows manufacturers to share vital information with healthcare payers and plans while treatments are pending Food and Drug Administration (FDA) approval, was passed by the House of Representatives and is awaiting approval in the Senate. ” The PIE Act was included as Section 810 in the Food and Drug Amendments of 2022 (H.R.
This could in turn lead to payers or HTA bodies, such as the National Institute for Health and Care Excellence (NICE), issuing guidance to use a new drug, such as sugelimumab, ahead of other higher-priced options. This often leads to payer-favoured pricing negotiations, driving down price. About CRA and the Life Sciences Practice.
Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year. 1 The risk of death from sepsis increases by as much as 8 percent each hour the condition goes untreated.
Food and Drug Administration (FDA) 510(k) clearance and launch of the company’s upgraded AI-powered software. We are committed to continuous improvement to optimize the clinical utility of the Swoop® system while driving commercial adoption across leading institutions globally. Hyperfine, Inc., The Swoop® system received initial U.S.
10 The more than 350 program initiatives address economic stability, education access/quality, health care access/quality, neighborhood/built environment and social/community context, 2 and focus on 23 high-priority leading health indicators (LHIs) that impact major causes of death and disease in the United States.
Food and Drug Administration (FDA) for 510(k) clearance. The ALICE device is being contract manufactured by an end-to-end solution provider that offers New Product Introduction (NPI) services to mass production capabilities for leading medical electronic device companies. and Israel.
The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmission of a new drug application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adults with chronic kidney disease on dialysis who have had insufficient response or intolerance to a phosphate binder treatment.
The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled.
On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022. ECG leads).
The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals’ Eylea (aflibercept) injection to treat the retinopathy of prematurity (ROP) in preterm infants. For the first time, physicians will now have an FDA-approved medication in Eylea to treat this heartbreaking disease in these smallest of patients.”
In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).
In addition, the number of active substances detected in the environment has been increasing with unknown consequences for ecosystems and the accumulation of substances in food chains. German College of General Practitioners and Family Physicians (DEGAM). The required actions will be complicated, maybe even controversial. cited 23Apr].
In this podcast, I interview top medical sales reps and leading medical sales executives across the entire world. So it’s very much a disruptive technology that is truly changing the paradigm of how physicians are treating prostate cancer which is really exciting. 06:31 – Jaclene Corstorphine (Guest) Correct, correct.
In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. In the US, most physicians can only spend a day a week, which isn’t efficient, she says. “We
The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.
a leading US developer of next gen endoscope systems announces today the US Food and Drug Administration (FDA) has granted 510(k) clearance of its novel integrated 360° field of view colonoscope. Saneso Inc., “Our endoscopes are comfortably familiar in operation to traditional endoscopes.”
Combine that with a steady decline in private practice physicians due to patient volume loss, revenue loss, and increased medical supply costs—and disruptors are deftly filling in the cracks they’ve left behind. food or housing insecurity) and how they impact the health of your patient populations. Consumer-First Content is Essential.
Next, pharmacists review the participant’s genetic results – along with health data such as drug, lifestyle, and food interactions – to customize a “Medication Action Plan” that members’ physicians can access to determine which drugs should be prescribed to increase safety and efficacy.
Greg, having devoted 25 years to the company, shares his invaluable insights as a Senior District Service Manager, leading a dedicated team of clinical specialists. In this podcast, I interview top medical sales reps and leading medical sales executives across the entire world. 30:37 The physician, then, is the one that scrubs in.
These discussions can be initiated by HCPs ranging from physicians to advanced practice professionals. Jay Patel From our experience in patient research across many different treatments, we’ve defined several key insights on what may lead to nonadherence: Complex medication routines and patients feeling overwhelmed with their regimen.
a medical software innovator dedicated to enhancing clinical impact in ablation therapy, announced today that it has received 510(k) clearance from the USA Food and Drug Administration (FDA) for its VisAble.IO Techsomed Ltd., VisAble.IO “We are excited to receive 510(k) clearance for our VisAble.IO
Last year, lifileucel was previously plagued by a different delay, which was an inability to convince the US Food and Drug Administration (FDA) that its potency assays for TILs were robust enough to lead to a uniform product. Only 29% of patients successfully received the CAR-T product within 12 months, and 31.9%
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content